|
Study to Evaluate the Safety and Activity of TTX030 (Anti-CD39) in Combination with Budigalimab and/or Chemotherapy in Subjects with Advanced Solid Tumors (TTX-030-002) |
I |
|
|
Study to Evaluate the Safety and Activity of TTX030 (Anti-CD39) in Combination with Budigalimab and/or Chemotherapy in Subjects with Advanced Solid Tumors (TTX-030-002) |
I |
|
|
Study to Evaluate the Safety and Activity of TTX030 (Anti-CD39) in Combination with Budigalimab and/or Chemotherapy in Subjects with Advanced Solid Tumors (TTX-030-002) |
I |
|
|
The Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry (CONNECT) |
III |
|
|
Treatment Patterns, Outcomes, and Patient-Reported Health-Related Quality of Life: A Prospective Disease Registry of Patients with Mantle Cell Lymphoma Treated with Novel Agents (SUMMIT) |
|
|
|
Treatment Resistance Following AntiCancer Therapies (18150) |
|
|
|
Treatment with Ipilimumab and Nivolumab for Rare Cancers (DART: Dual Anti-CRLA-4 and Anti-PD-1 Blockade in Rare Tumors) (S1609) |
|
|
|
Trial Comparing Paclitaxel, Ifosfamide, and Cisplatin with High-Dose Chemo Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors (A031102) |
III |
|
|
Trial of Neoadjuvant AMG-232 Concurrent with Preoperative Radiotherapy in Wild-Type P53 Soft Tissue Sarcoma (DT001) |
I |
|
|
Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum (GY019) |
III |
|
|
Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (GU006) |
II |
|
|
Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (A021703) |
III |
|
|
Trial to Assess the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab in Participants with Advanced Melanoma Previously Exposed to an Anti-PD-1/L1 Agent (LEAP004) |
|
|
|
Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy (S1418) |
III |
|
|
Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer (AFT-38) |
III |
|
|
Umbrella Study with Rolling Arms of Investigational Agents with either Pembrolizumab in combination with Chemotherapy or with Pembrolizumab alone in Patients with Advanced Non- small cell Lung Cancer (MK3475-U01) |
II |
|
|
Window Study of SAR439859 Versus Letrozole in ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer |
II |
|
